IFNL2: A Potential Drug Target and Biomarker (G282616)

Target Name: IFNL2

NCBI ID: G282616

IFNL2

IFNL2: A Potential Drug Target and Biomarker

Interleukin 28A (IL-28A), also known as interferon lambda 2, is a cytokine that plays a crucial role in the regulation of immune responses and inflammation. It is expressed in a variety of tissues, including immune cells, and has been implicated in a wide range of biological processes, including immune surveillance, tissue repair, and cellular signaling.

IFNL2 has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. In this article, we will explore the biology and potential therapeutic applications of IFNL2, with a focus on its role as a drug target and biomarker.

IFNL2 as a Drug Target

IFNL2 has been shown to play a role in a variety of cellular signaling pathways, including the production of cytokines and chemokines, cell survival, and the regulation of cellular immigration. It is a key regulator of the T cell response, and has been shown to promote the development of CD4+ T cells, which are crucial for immune surveillance and defense against infections.

IFNL2 has also been shown to play a role in the regulation of cancer cell growth and survival. For example, studies have shown that high levels of IFNL2 are associated with poor prognosis in cancer patients, and that inhibition of IFNL2 has been shown to improve survival in a variety of cancer types.

IFNL2 as a Biomarker

IFNL2 has also been used as a biomarker for a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. For example, studies have shown that high levels of IFNL2 are associated with the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

IFNL2 has also been shown to be an effective biomarker for cancer, as high levels of IFNL2 are associated with poor prognosis in cancer patients. Additionally, studies have shown that IFNL2 levels are elevated in a variety of cancer types, and that inhibition of IFNL2 has been shown to improve survival in these diseases.

IFNL2 as a Potential therapeutic

IFNL2 has the potential to be a therapeutic target for a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Studies have shown that targeting IFNL2 with small molecules or antibodies has the potential to improve treatment outcomes in these diseases.

For example, studies have shown that inhibition of IFNL2 with small molecules has the potential to improve survival in cancer patients. Additionally, studies have shown that IFNL2 is an effective biomarker for a variety of neurodegenerative diseases, and that targeting IFNL2 with diagnostic tests or therapies has the potential to improve treatment outcomes in these diseases.

IFNL2 as a biomarker

IFNL2 has also been shown to be an effective biomarker for a variety of diseases, including cancer, autoimmune disorders, and neurodegenerative diseases. Studies have shown that high levels of IFNL2 are associated with the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Additionally, studies have shown that IFNL2 levels are elevated in a variety of cancer types, and that inhibition of IFNL2 has been shown to improve survival in these diseases.

IFNL2 as a potential drug target

IFNL2 has been shown to play a role in a variety of cellular signaling pathways, including the production of cytokines and chemokines, cell survival, and the regulation of cellular immigration. It is a key regulator of the T cell response, and has been shown to promote the development of CD4+ T cells, which are crucial for immune surveillance and defense against infections

Protein Name: Interferon Lambda 2

Functions: Cytokine with antiviral, antitumour and immunomodulatory activities. Plays a critical role in the antiviral host defense, predominantly in the epithelial tissues. Acts as a ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IFNLR1, and receptor engagement leads to the activation of the JAK/STAT signaling pathway resulting in the expression of IFN-stimulated genes (ISG), which mediate the antiviral state. Has a restricted receptor distribution and therefore restricted targets: is primarily active in epithelial cells and this cell type-selective action is because of the epithelial cell-specific expression of its receptor IFNLR1. Seems not to be essential for early virus-activated host defense in vaginal infection, but plays an important role in Toll-like receptor (TLR)-induced antiviral defense. Plays a significant role in the antiviral immune defense in the intestinal epithelium. Exerts an immunomodulatory effect by up-regulating MHC class I antigen expression

The "IFNL2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFNL2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets